Get started
TELADOC HEALTH INCTELADOC HEALTH INCTELADOC HEALTH INC

TELADOC HEALTH INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

TDOC trade ideas

4000% return with Teladoc Health, Inc** long term investment ** On the above 10 day chart price action has corrected 97% since February 2021. A number of reasons now exist to be bullish, they include: 1) Price action and RSI resistance breakouts. Almost 4 years of resistance. 2) Regular positive divergence. Multiple oscillators print positive divergence over a 90 day period. 3) No stock splits. 4) 15% short interest. Who does that after a 97% correction? 5) The falling wedge forecast as measured from top and lower touch points calls for a macro move to the $400 area. Is it possible price action corrects further after 97%? Sure, sellers love it. Is it probable? No Ww Type: Investment Risk: you decide Timeframe for long: Ask me after it pops up 100%, you always do. Return: 2000-4000% Stop loss: will say elsewhere
NYSE:TDOCLong
by without_worries
24
TDOC 1 Day ChartMany thanks to @without_worries, for bringing this asset to our attention. He is a very wise man. Here we have this asset per the chart a golden cross ( 200 and 50 SMA) is highly probable in a few days but not definite. There is a long wick candle resting on the 50 SMA and 50 EMA after some bearish activity alluding to a possible reversal. The long wick candle is also resting on a resistance turn support level. The long wick candle is also currently residing in a FVG. The CM_Williams_Vix_Fix bottom indicator is also flashing saying the bottom is in or is being formed, and the Stochastic RSI is in the oversold zone. RSI levels are healthy. And the price action is *currently* in an upward parallel channel. Be very careful. The market is a strange place. We need a miracle.
NYSE:TDOC
by paper_Trader1775
2
Telehealth Triumph!Teladoc Health is building bullish momentum, with a gap forming around the $7.50 level. A breakout above the $10.66 resistance would signal further strength, positioning the stock to reach the $15.02 weekly resistance. This setup offers an appealing risk-to-reward ratio, with downside managed by a $7.13 stop-loss. In the longer term, TDOC has the potential to reach $21.60, driven by the rising demand for telemedicine and digital health solutions. As healthcare increasingly moves toward virtual care, Teladoc’s innovative platform and expanding service offerings position it well for growth. With strategic partnerships and increasing adoption, Teladoc stands to capture a growing share of the telehealth market, supporting both short-term momentum and long-term value. This combination of technical momentum and strong market fundamentals supports a bullish push toward $15.02 in the near term, with potential to reach $21.60 in the longer run. Follow @The_Trading_Mechanic for more health check-ups on your investments! NYSE:TDOC
NYSE:TDOCLong
by The_Trading_Mechanic
3
Teladoc emerging from a 3 year downtrendTeladoc (TDOC) Trade Idea 📈 I'm seeing a potential breakout from a 3-year downtrend, and the chart on the Daily Timeframe is forming a classic Cup and Handle pattern. If the pattern plays out, it suggests a bullish continuation, and we could see a significant move to the upside. Targeting a potential 50% increase, which aligns with the projected pattern measurement. This setup offers a favorable risk-to-reward ratio for long positions. 🚀 Key Levels to Watch: Support: $9.19 Resistance: $22.32 Target 1: $14.29 Final Target: $20.15 Let’s watch to see if the breakout picks up steam! Keep it simple and trade wisely.
NYSE:TDOCLong
by TrellTrades
1
Teladoc partners with Brightline to expand into paediatricTeladoc Health Inc., a leader in the US telemedicine market, has announced a strategic partnership with Brightline, a digital platform specialising in mental health care for children, adolescents, and their families. This partnership marks Teladoc's entry into a new and promising healthcare market segment, focusing on paediatric mental health – a critical area of growing need. Through this collaboration, Teladoc Health will integrate Brightline's expertise in paediatric psychology and psychiatry into its telemedicine service, offering access to specialised care for a sensitive and complex patient group. This move expands Teladoc's service range and positions it at the forefront of addressing the rising mental health challenges among younger populations. Technical analysis of Teladoc Health Inc. (NYSE: TDOC) Let us explore the potential trading opportunities based on the current technical setup of Teladoc's stock: Timeframe : Daily (D1) Current trend : the stock is showing signs of the beginning of an uptrend Resistance level : 10.15 USD Support level : 9.25 USD Potential downtrend target : if the stock enters a downtrend, the downside target could be around 8.70 USD Short-term target : if the uptrend continues and the stock breaches the resistance at 10.15 USD, a short-term target could be set at 11.85 USD Medium-term target : with sustained positive momentum, the stock price might rise to 13.40 USD Investors should closely monitor Teladoc Health's performance, particularly in light of this new partnership with Brightline. Integrating specialised paediatric mental health services could significantly enhance Teladoc's market position and potentially increase stock value as the company taps into this underserved sector. — Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews. The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments. Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65.68% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
NYSE:TDOC
by RoboMarkets
TDOC may bring a lot of profit??1) RSI's 2 moving averages have crossed already each other. Purple one went above green one and it is buy sign. Also RSI's Resistance Line was broken. 2) MACD shows that: Upper trend is gaining power because green bars are lengthing and it is dark green not light green. 3) Momentum Resistance Line did not work. Momentum increased a lot but it is still less than 0. It shows that: Down trend is losing its power but it may still decrease because it is less than 0. When it goes above 0 line it will be another buy sign. On the other hand, i drew support line of Momentum. If support line is not broken, it will be more than 0 and trend will go upper. 4) CCI's 0 line can be used for strategy and it is very important for some securities which lost its value more than %90. This is experience. If CCI cuts above 0 line, it will be buy sign. 5) This is not certain but may work why not. Target Price = (Highest price level + Lowest price level)/2 Target Price = 161$ ???? ALL COMMENTS DO NOT INCLUDE INVESTING ADVICE!!!
NYSE:TDOCLong
by Emirhanhmc
8
6/13/24 - $tdoc - interesting sub $10, but want <$86/13/24 :: VROCKSTAR :: NYSE:TDOC revisiting this one b/c i had flagged to myself to "not care" until we hit $10. well here we are on 6/13, at $10. so what gives, do we start buying, get interested or just hand sit. my bias is to hand sit still. the tape is dramatically different than when i made this comment in early april - and this company as well as others that are "unprofitable, not opex leverage inducing, not growing like a weed"... the market says i don't want. we gotta respect mr. market. those r the rules fam. so what's this thing objectively worth given meager (LSD - low single digit) sales growth? given no opex leverage? given they seem to be a marginal share loser in what would seem like a promising category of telemedicine that defn got a pull-forward from covid but is still giving some back... trends.google.com i'd posit one way to look at this is to use my R&D rule of thumb. at 25% discount rate at $350 mm a year invested then double that - it's $2.8 bn - a 25-30% bump from the enterprise value today. but the mkt won't pay for that logic - bc the results suggest the discount rate on R&D is either unknowable or much much higher. so $2.8 bn is the ceiling valuation. and 25-30% upside isn't amazing (we just did 15% a day in NASDAQ:AVGO results - so that's the bar guys, good charts, good results, rips). at $8 we basically get this thing at a discount to gross profit, which buys us some time to turn that opex inflection, see a few quarters and probably not go too much lower and it's in play (take out potential). conclusion - for those who know the company well, and if ops r looking decent - it's an obvious buy here - very shorted. but for me - that covers everything, i just don't see the allure of jumping into a difficult turn around, chart, financials. i need a heady discount. so i'm setting a flag at $8 and we update this thinking if/as we get there. and if it just rips from here, we let it go. congratulate those putting their nuts on the line. but i won't be one, not yet and not in this tape V
NYSE:TDOC
by VROCKSTAR
Teladoc: Bearish on American Mental Health? Bullish on TDOCTDOC provides video therapy and telehealth services. They blew up their stock price buy wasting 12Bn on a useless acquisition because the executives got a bit too excited and horny to spend their cash during the COVID bubble. Nonetheless, revenues are linearly growing, and American mental health is in rapid, precipitous, unstoppable decline. There is some concern that LLM's or AI will take away the market share for therapists and human therapy, but I think that actually, personally, AI interactions on a daily basis will make humans more willing to pay for the human interaction provided by Teladoc therapists, even if it is contrived. Nonetheless, I'm a technical analyst first and foremost, there is a clear stop, we had the final rage sell already, and there is a clear mean reversion target on the recovery rally. I think it would be wise to have a TP1 at $80, but I am ultimately targeting 155 as laid out in the chart. This is a $3.5Bn company so it's not as though this piece is a cheap pump.
NYSE:TDOCLong
by wantonwallet
Teladoc's Bumpy Ride: From Telemedicine Champion to Flop Teladoc Health Inc. (NYSE: NYSE:TDOC ) once stood as a beacon of hope in the realm of healthcare innovation, poised to revolutionize the way people access medical services through telemedicine. However, what was once a soaring success story has now become a cautionary tale of overambition and strategic missteps, as evidenced by the company's staggering decline in stock price and ongoing struggles to meet investor expectations. The Rise and Fall: In the midst of the COVID-19 pandemic, Teladoc's ( NYSE:TDOC ) stock skyrocketed to unprecedented heights, reaching a peak of $308.28 per share. Yet, this euphoria was short-lived, as the company's value plummeted to less than $20, marking one of the most dramatic collapses witnessed in recent years. The catalyst for this downfall? A series of strategic blunders, most notably, the ill-fated $18 billion acquisition of Livongo Health. The Livongo Debacle: Teladoc's ( NYSE:TDOC ) acquisition of Livongo Health was meant to be a game-changer, a strategic move that would cement its position as a dominant force in the healthcare industry. However, what ensued was a costly mistake that sent shockwaves through the market. The deal, which initially seemed promising, quickly soured, resulting in a staggering $13 billion noncash impairment charge and a significant erosion of shareholder value. Financial Turbulence: The repercussions of Teladoc's ( NYSE:TDOC ) missteps were felt acutely in its financial performance. Despite once being hailed as a growth story, the company's revenue growth has stagnated, with fourth-quarter revenues rising by a meager 4% year-over-year to $661 million, falling short of analyst estimates. Additionally, Teladoc's ( NYSE:TDOC ) guidance for future revenue growth has been tepid at best, with projections suggesting a paltry 2.5% increase. Challenges Ahead: Teladoc's ( NYSE:TDOC ) woes extend beyond its financial struggles. The company faces mounting challenges in a post-pandemic landscape, with the allure of virtual healthcare waning as traditional clinics and hospitals reopen their doors. Moreover, attempts to capitalize on upselling opportunities have faltered, leaving Teladoc grappling with a shrinking market and dwindling investor confidence. Market Outlook: As Teladoc ( NYSE:TDOC ) braces for further turbulence, analysts predict a grim future for the once-promising stock. With expectations of downward revisions to earnings estimates looming on the horizon, the company's shares are poised to experience further declines, potentially plummeting to a low of $15 per share, representing a staggering 30% drop from recent levels.
NYSE:TDOC
by DEXWireNews